Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan

Yoshie Onishi, Shiro Hinotsu, Yoko M. Nakao, Hisashi Urushihara, Koji Kawakami

研究成果: Article

3 引用 (Scopus)

抄録

Objectives: The clinical efficacy of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin) therapy in cardiovascular disease has been established in clinical trials. Nonetheless, it is unclear to whom and when statin treatment should be initiated for patients without cardiovascular disease with regard to overall absolute risk reduction of cardiovascular disease and the cost-effectiveness of long-term statin therapy. The objective of this study was to examine the cost-effectiveness of pravastatin 10 mg/d compared with no-drug therapy for primary prevention of coronary artery disease (CAD), using cardiac risk factors from risk predictions for CAD from Japanese cohort studies. Methods: A Markov transition model was used to evaluate the cost-effectiveness of pravastatin compared with no-drug therapy. The incidence of acute myocardial infarction was estimated by using risk predictions for CAD in Japan. A hypothetical population from 45 to 75 years old was examined by using the cardiac risk factors. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio over a lifetime horizon were estimated from a perspective of payers. Results: Incremental cost-effectiveness ratios of pravastatin therapy compared with no-drug therapy were 9,677,000 yen per QALY in 55-year-old men and 8,648,000 yen per QALY in 65-year-old men with diabetes mellitus, hypertension (grade II), and smoking as cardiac risk factors. Pravastatin therapy was not cost-effective compared with no-drug therapy in all subgroups evaluated. Conclusions: Using risk prediction for CAD based on a Japanese cohort with no history of cardiovascular events, the cost-effectiveness of pravastatin for primary prevention of CAD may not be cost-effective in populations at both low and high cardiac risk.

元の言語English
ページ(範囲)5-12
ページ数8
ジャーナルValue in Health Regional Issues
2
発行部数1
DOI
出版物ステータスPublished - 2013 5
外部発表Yes

Fingerprint

Pravastatin
Primary Prevention
Cost-Benefit Analysis
Coronary Artery Disease
Japan
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Quality-Adjusted Life Years
Drug Therapy
Cardiovascular Diseases
Therapeutics
Costs and Cost Analysis
Numbers Needed To Treat
Cost of Illness
Population
Therapy
Economic evaluation
Coronary artery disease
Prediction
Diabetes Mellitus
Oxidoreductases

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Economics, Econometrics and Finance (miscellaneous)

これを引用

Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan. / Onishi, Yoshie; Hinotsu, Shiro; Nakao, Yoko M.; Urushihara, Hisashi; Kawakami, Koji.

:: Value in Health Regional Issues, 巻 2, 番号 1, 05.2013, p. 5-12.

研究成果: Article

@article{978011d3aaaf430485fe5ec008969ec9,
title = "Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan",
abstract = "Objectives: The clinical efficacy of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin) therapy in cardiovascular disease has been established in clinical trials. Nonetheless, it is unclear to whom and when statin treatment should be initiated for patients without cardiovascular disease with regard to overall absolute risk reduction of cardiovascular disease and the cost-effectiveness of long-term statin therapy. The objective of this study was to examine the cost-effectiveness of pravastatin 10 mg/d compared with no-drug therapy for primary prevention of coronary artery disease (CAD), using cardiac risk factors from risk predictions for CAD from Japanese cohort studies. Methods: A Markov transition model was used to evaluate the cost-effectiveness of pravastatin compared with no-drug therapy. The incidence of acute myocardial infarction was estimated by using risk predictions for CAD in Japan. A hypothetical population from 45 to 75 years old was examined by using the cardiac risk factors. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio over a lifetime horizon were estimated from a perspective of payers. Results: Incremental cost-effectiveness ratios of pravastatin therapy compared with no-drug therapy were 9,677,000 yen per QALY in 55-year-old men and 8,648,000 yen per QALY in 65-year-old men with diabetes mellitus, hypertension (grade II), and smoking as cardiac risk factors. Pravastatin therapy was not cost-effective compared with no-drug therapy in all subgroups evaluated. Conclusions: Using risk prediction for CAD based on a Japanese cohort with no history of cardiovascular events, the cost-effectiveness of pravastatin for primary prevention of CAD may not be cost-effective in populations at both low and high cardiac risk.",
keywords = "Coronary artery disease, Cost-effectiveness, Pravastatin, Primary prevention",
author = "Yoshie Onishi and Shiro Hinotsu and Nakao, {Yoko M.} and Hisashi Urushihara and Koji Kawakami",
year = "2013",
month = "5",
doi = "10.1016/j.vhri.2013.02.003",
language = "English",
volume = "2",
pages = "5--12",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan

AU - Onishi, Yoshie

AU - Hinotsu, Shiro

AU - Nakao, Yoko M.

AU - Urushihara, Hisashi

AU - Kawakami, Koji

PY - 2013/5

Y1 - 2013/5

N2 - Objectives: The clinical efficacy of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin) therapy in cardiovascular disease has been established in clinical trials. Nonetheless, it is unclear to whom and when statin treatment should be initiated for patients without cardiovascular disease with regard to overall absolute risk reduction of cardiovascular disease and the cost-effectiveness of long-term statin therapy. The objective of this study was to examine the cost-effectiveness of pravastatin 10 mg/d compared with no-drug therapy for primary prevention of coronary artery disease (CAD), using cardiac risk factors from risk predictions for CAD from Japanese cohort studies. Methods: A Markov transition model was used to evaluate the cost-effectiveness of pravastatin compared with no-drug therapy. The incidence of acute myocardial infarction was estimated by using risk predictions for CAD in Japan. A hypothetical population from 45 to 75 years old was examined by using the cardiac risk factors. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio over a lifetime horizon were estimated from a perspective of payers. Results: Incremental cost-effectiveness ratios of pravastatin therapy compared with no-drug therapy were 9,677,000 yen per QALY in 55-year-old men and 8,648,000 yen per QALY in 65-year-old men with diabetes mellitus, hypertension (grade II), and smoking as cardiac risk factors. Pravastatin therapy was not cost-effective compared with no-drug therapy in all subgroups evaluated. Conclusions: Using risk prediction for CAD based on a Japanese cohort with no history of cardiovascular events, the cost-effectiveness of pravastatin for primary prevention of CAD may not be cost-effective in populations at both low and high cardiac risk.

AB - Objectives: The clinical efficacy of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin) therapy in cardiovascular disease has been established in clinical trials. Nonetheless, it is unclear to whom and when statin treatment should be initiated for patients without cardiovascular disease with regard to overall absolute risk reduction of cardiovascular disease and the cost-effectiveness of long-term statin therapy. The objective of this study was to examine the cost-effectiveness of pravastatin 10 mg/d compared with no-drug therapy for primary prevention of coronary artery disease (CAD), using cardiac risk factors from risk predictions for CAD from Japanese cohort studies. Methods: A Markov transition model was used to evaluate the cost-effectiveness of pravastatin compared with no-drug therapy. The incidence of acute myocardial infarction was estimated by using risk predictions for CAD in Japan. A hypothetical population from 45 to 75 years old was examined by using the cardiac risk factors. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio over a lifetime horizon were estimated from a perspective of payers. Results: Incremental cost-effectiveness ratios of pravastatin therapy compared with no-drug therapy were 9,677,000 yen per QALY in 55-year-old men and 8,648,000 yen per QALY in 65-year-old men with diabetes mellitus, hypertension (grade II), and smoking as cardiac risk factors. Pravastatin therapy was not cost-effective compared with no-drug therapy in all subgroups evaluated. Conclusions: Using risk prediction for CAD based on a Japanese cohort with no history of cardiovascular events, the cost-effectiveness of pravastatin for primary prevention of CAD may not be cost-effective in populations at both low and high cardiac risk.

KW - Coronary artery disease

KW - Cost-effectiveness

KW - Pravastatin

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84877157581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877157581&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2013.02.003

DO - 10.1016/j.vhri.2013.02.003

M3 - Article

AN - SCOPUS:84877157581

VL - 2

SP - 5

EP - 12

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

IS - 1

ER -